Hatem Abou-Sayed
Gründer bei ELEVAI LABS INC.
Vermögen: 924 664 $ am 30.04.2024
Profil
Hatem Abou-Sayed is the founder of Elevai Labs, Inc. founded in 2020, where he holds the title of Director & Chief Medical Officer.
He is currently a Director at Fruit Street Health, P.B.C.
and a Managing Member at Zamzam Skin, LLC since 2017.
Dr. Abou-Sayed was a Vice-President at Interpreta, Inc. from 2015 to 2017.
He holds an MBA from Northwestern University, an undergraduate degree from the University of California, Berkeley, and a doctorate from the University of California Irvine School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ELEVAI LABS INC.
7,92% | 25.03.2024 | 1 371 905 ( 7,92% ) | 924 664 $ | 30.04.2024 |
Aktive Positionen von Hatem Abou-Sayed
| Unternehmen | Position | Beginn |
|---|---|---|
| ELEVAI LABS INC. | Gründer | 01.01.2020 |
Fruit Street Health, P.B.C.
 Fruit Street Health, P.B.C. Internet Software/ServicesTechnology Services Fruit Street Health, Inc. develops software applications for the healthcare professionals. It offers digital health and telemedicine to deliver the Center for Disease Control & Prevention’s (CDC’s) National Diabetes Prevention Program (DPP). It helps to prevent and treat lifestyle related disease using telemedicine, connected devices and mobile applications. The company was founded by Laurence Girard in 2014 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Hatem Abou-Sayed
| Unternehmen | Position | Ende |
|---|---|---|
Interpreta, Inc.
 Interpreta, Inc. Internet Software/ServicesTechnology Services Part of Centene Corp., Interpreta, Inc. is a healthcare analytics company that continuously updates, interprets, and synchronizes clinical data to create personalized roadmaps for timely care. The company is based in San Diego, CA. The company's real-time insights provide guidance to physicians, care managers, and health plans for quality improvement, clinical prioritization, population management, and precision medicine. The company was founded by Ahmed F. Ghouri, who has been the CEO since incorporation. Interpreta was acquired by Centene Corp. on March 27, 2018 for $175.92 million. | Corporate Officer/Principal | 01.01.2017 |
Ausbildung von Hatem Abou-Sayed
| University of California, Berkeley | Undergraduate Degree |
| University of California Irvine School of Medicine | Doctorate Degree |
| Northwestern University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ELEVAI LABS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Fruit Street Health, P.B.C.
Fruit Street Health, P.B.C. Internet Software/ServicesTechnology Services Fruit Street Health, Inc. develops software applications for the healthcare professionals. It offers digital health and telemedicine to deliver the Center for Disease Control & Prevention’s (CDC’s) National Diabetes Prevention Program (DPP). It helps to prevent and treat lifestyle related disease using telemedicine, connected devices and mobile applications. The company was founded by Laurence Girard in 2014 and is headquartered in New York, NY. | Technology Services |
Interpreta, Inc.
Interpreta, Inc. Internet Software/ServicesTechnology Services Part of Centene Corp., Interpreta, Inc. is a healthcare analytics company that continuously updates, interprets, and synchronizes clinical data to create personalized roadmaps for timely care. The company is based in San Diego, CA. The company's real-time insights provide guidance to physicians, care managers, and health plans for quality improvement, clinical prioritization, population management, and precision medicine. The company was founded by Ahmed F. Ghouri, who has been the CEO since incorporation. Interpreta was acquired by Centene Corp. on March 27, 2018 for $175.92 million. | Technology Services |
